TI
SBBP

Telemetry Investments’s Strongbridge Biopharma plc. SBBP Stock Holding History

Telemetry Investments’s Portfolio SBBP Stock Details SBBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-124,544
Closed -$620K – 116
2019
Q1 		$620K Buy
+124,544
New +$613K 0.31% 44

Other funds holding SBBP

CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Telemetry Investments's SBBP Position: Q2 2019 in Review

Telemetry Investments sold out of Strongbridge Biopharma plc. (SBBP) in Q2 2019, closing a stake of 124,544 shares — an estimated $620K sold.

Telemetry Investments first reported a position in SBBP in Q1 2019 and held it in 1 quarter. The position peaked at $620K in Q1 2019. 58 funds tracked by Wall St. Rank hold SBBP as of Q2 2019.

  • Telemetry Investments reported no remaining Strongbridge Biopharma plc. position as of Q2 2019 after selling out during the quarter.
  • Telemetry Investments sold 124,544 Strongbridge Biopharma plc. shares in Q2 2019, an estimated $620K.
  • Telemetry Investments first reported a position in Strongbridge Biopharma plc. in Q1 2019 and held it in 1 quarter.
  • Telemetry Investments's Strongbridge Biopharma plc. position peaked at $620K in Q1 2019.
  • 58 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q2 2019.

Based on Telemetry Investments's 13F filing for Q2 2019, filed 14 Aug 2019.